Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely however we are beginning to have limited access to the office from 6th July 2020. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Advanced
Trials portfolio
EACH
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer
The safety run-in will be of a single arm de-escalating design which will recruit up to 16 patients with a variety of recurrent and/or metastatic squamous cell carcinomas. The modified Continual Reass [...]
Area: Head & neck cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
HiLo
Multicentre randomised trial of high dose versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation following surgery for differentiated thyroid cancer.
HiLo was a randomised, phase III factorial randomised trial, stratified according to trial site, T stage and N stage.
Area: Head & neck cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
IoN
Is ablative radiOiodine Necessary for low risk patients.
IoN is a randomised, non-blind, non-inferiority phase III multicentre trial, randomised using the minimisation method and stratified according to site, patient age, T Stage and N Stage to decide if pa [...]
Area: Head & neck cancer
Phase: Phase II/III
Status: In follow-up (non-recruiting)
ORCA-2
ORCA-2: a phase I study of olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (NHSCC).
ORCA-2 is a phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC). The [...]
Area: Head & neck cancer
Phase: Phase I
Status: In follow-up (non-recruiting)
POPPY
A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck.
POPPY is a single-arm phase II trial which aims to evaluate the safety and anti-tumour activity of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer and a perfo [...]
Area: Head & neck cancer
Phase: Phase II
Status: Active (recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2020 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us